Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN359868 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Fms-Related tyrosine Kinase 3 (FLT3) (N-Term) antibody
- Antibody type
- Polyclonal
- Antigen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human FLT3.
- Description
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- N-Term
- Vial size
- 0.4 mL
- Concentration
- 0.25 mg/mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Voluntary spatial attention has different effects on voluntary and reflexive saccades.
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.
FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
Seidlits SK, Reza T, Briand KA, Sereno AB
TheScientificWorldJournal 2003 Sep 15;3:881-902
TheScientificWorldJournal 2003 Sep 15;3:881-902
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.
Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T
Blood 2003 Oct 15;102(8):2969-75
Blood 2003 Oct 15;102(8):2969-75
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F
Blood 2003 Oct 1;102(7):2387-94
Blood 2003 Oct 1;102(7):2387-94
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.
Kottaridis PD, Gale RE, Linch DC
Leukemia & lymphoma 2003 Jun;44(6):905-13
Leukemia & lymphoma 2003 Jun;44(6):905-13
FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
Galimberti S, Rossi A, Palumbo GA, Morabito F, Guerrini F, Vincelli I, Fazzi R, Santini V, Petrini M
Anticancer research 2003 Jul-Aug;23(4):3419-26
Anticancer research 2003 Jul-Aug;23(4):3419-26
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- Western blot analysis of anti-FLT3 Pab in HL-60 cell lysate. FLT3 (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.
